SCHEMBL16615211

SCHEMBL16615211

O=C(Nc1ccc(C(=O)N2CCCC2)cc1)c1cc2c(nn1)NCCN2Cc1cc(Cl)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 6/20 0.53
MAPT P10636 4/20 0.45
HPGD P15428 3/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
F10 P00742 2/20 0.41
CCNC P24863 2/20 0.40
CDK8 P49336 2/20 0.40
PKM P14618 1/20 0.39
RECQL P46063 1/20 0.39
HSD11B1 P28845 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MET P08581 1/20 0.38
MAP4K2 Q12851 1/20 0.38
MAP3K1 Q13233 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
Q6ZSR9 Q6ZSR9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17918724 0.94 CCNC (0.47) ALKMAPTCCNCCDK8MET
SCHEMBL16615113 0.93 ALK (0.47) ALKMAPTHPGDKMT2ACCNC
SCHEMBL17918714 0.93 ALK (0.45) ALKMAPTHPGDALDH1A1MEN1
SCHEMBL18106074 0.91 ALK (0.44) ALKMAPTKMT2AF10CCNC
SCHEMBL16615157 0.88 ALK (0.51) ALKMEN1KMT2ANPC1RAB9A
SCHEMBL16615212 0.86 MET (0.45) ALKMAPTHPGDALDH1A1MEN1
SCHEMBL17918855 0.84 ALK (0.59) ALKMAPTHPGDMETMAP4K2
SCHEMBL17918786 0.84 ALK (0.46) ALKALDH1A1KMT2ANPC1RAB9A
SCHEMBL18106063 0.84 CFTR (0.47) ALKNPC1RAB9ACCNCCDK8
SCHEMBL17918706 0.83 MAPT (0.44) ALKMAPTHPGDALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695182-B2 Chemical compounds (derivatives) and their application for the treatment of oncological diseases LIMITED LIABILITY COMPANY “NATIONAL PHARMACEUTICAL TECHNOLOGIES” (RU) 2017-07-04 US disclosed
EP-3050884-A1 NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES Limited Liability Company "National Pharmaceutical (RU) 2016-08-03 EP disclosed
US-20160200729-A1 NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES LIMITED LIABILITY COMPANY (RU) 2016-07-14 US disclosed
WO-2015047133-A1 NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ОТЕЧЕСТВЕННЫЕ ФАРМАЦЕВТИЧЕСКИЕ ТЕХНОЛОГИИ" 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200729-A1 NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES BRAF, CNKSR1, RAF1 ALK 1031/4885MAPT 2274/4885HPGD 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.